Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation.
about
The role of sphingosine-1-phosphate in endothelial barrier functionActivation of RhoA, but Not Rac1, Mediates Early Stages of S1P-Induced Endothelial Barrier EnhancementMorphine for the treatment of pain in sickle cell diseaseMorphine induces expression of platelet-derived growth factor in human brain microvascular endothelial cells: implication for vascular permeabilityIn vitro and in vivo antagonism of a G protein-coupled receptor (S1P3) with a novel blocking monoclonal antibodyDendritic cell sphingosine 1-phosphate receptor-3 regulates Th1-Th2 polarity in kidney ischemia-reperfusion injury.Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitorsPaxillin mediates stretch-induced Rho signaling and endothelial permeability via assembly of paxillin-p42/44MAPK-GEF-H1 complex.Functional promoter variants in sphingosine 1-phosphate receptor 3 associate with susceptibility to sepsis-associated acute respiratory distress syndrome.Increased μ-opioid receptor expression in metastatic lung cancerMorphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer.Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung.Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection.Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection.Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer.The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigationMorphine use in cancer surgeryKnock out of S1P3 receptor signaling attenuates inflammation and fibrosis in bleomycin-induced lung injury mice model.Lysophosphatidic acid receptor 1 modulates lipopolysaccharide-induced inflammation in alveolar epithelial cells and murine lungs.Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Hyaluronan regulation of vascular integrityChemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic moleculesExtracellular Vesicles from Caveolin-Enriched Microdomains Regulate Hyaluronan-Mediated Sustained Vascular Integrity.Effect of mu Agonists on Long-Term Survival and Recurrence in Nonsmall Cell Lung Cancer Patients.Sphingosine-1-phosphate receptor-3 is a novel biomarker in acute lung injuryEndogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethalityRegulation of vascular permeability by sphingosine 1-phosphate.Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.Sphingosine-1-phosphate receptor 3 influences cell cycle progression in muscle satellite cells.Vascular and dendritic cell coagulation signaling in sepsis progression.Sphingosine 1-phosphate in coagulation and inflammation.The roles of thrombin and protease-activated receptors in inflammation.Endothelium--role in regulation of coagulation and inflammation.Barrier enhancing signals in pulmonary edema.Regional anaesthesia and cancer metastases: the implication of local anaesthetics.Impact of anesthesia for cancer surgery: Continuing professional development.Endothelial nanomedicine for the treatment of pulmonary disease.Endothelial barrier dysfunction in septic shock.The mu opioid receptor: A new target for cancer therapy?Sphingosine-1-Phosphate Signaling in Endothelial Disorders.
P2860
Q26862336-30FD4132-610C-4DC3-889A-9D94C49B1DD2Q27346879-900B259E-BE86-4CC5-A649-2E9024A54DCEQ28087296-79D76146-3767-4773-98C3-1DDE4A6471A9Q28478866-1EAEAD32-21D3-44C4-B059-C19358427249Q28482145-79365296-AF25-4868-8B8D-4A5DF856493AQ30423883-234FB960-C3E5-44E2-B292-275B31C56A85Q33702325-9101F3E5-9AED-4F10-AABE-6666D4AAC66AQ33775159-769F739C-607D-4330-A0AB-CE10793DD7FFQ33816773-31D30200-6E26-4156-AAFB-2D325734B489Q33951500-0ADE0923-6E0E-4979-9DFE-AB4617B38ECBQ33951506-9C6D4B28-B822-4A92-9AF4-F0140104BC9DQ34184813-006B72BF-228F-409E-BCFB-561F2EF1CC6AQ34475362-A7F00BBC-B33B-4C33-97AD-BDF8248F123AQ34707273-1719384D-BA1C-4D3D-A83E-A887EA015D33Q35011905-E0CCB458-8C74-4374-9D5A-C228DD70FE5FQ35083162-9109CF57-6FB3-4222-98BB-BD0F11B9D574Q35151843-59CD34E0-FE14-4553-9B01-49BE42BBE2C3Q35242288-0B5B6F1B-65D3-4401-9D82-1BBE32DE2F6EQ35325265-BF92652B-DAE7-4499-AE60-2B8CDE42E456Q35551835-F3325F59-D16C-4657-ADF8-4375FAF35F6BQ35660196-ABC2AA46-A941-4B0A-80A5-ED2187A9B5B8Q35684358-37C979BB-CAAE-4BDA-86A2-1F1AF174D241Q36089279-B02AFC19-9794-4FAE-A56D-C1D46F138361Q36194004-F6DE96E2-A7AE-44E3-9D8F-5B0B8D71D9E5Q36539650-FE2E16C0-2025-492B-A360-428225047515Q37142196-4BFC55D2-EFE6-4397-B131-3B40F2E0E556Q37219703-12C7F90E-5C9F-4980-8250-5422FF504442Q37241529-3EED9D17-49E4-41E0-8388-43A1A1475C1DQ37504736-3AA858E5-CF92-4992-A72E-06C7F1AA328CQ37561489-12A143B5-A495-47F3-86E2-4E9037A74012Q37909176-09EA15ED-10F4-487C-9DDA-A1F9F7FE4CE5Q37910045-D40BEB3A-2BD1-4A0F-B950-9424E2B6938BQ37918456-4D6A0DCC-873B-40A2-BA98-34572232F5B5Q38110515-6897627B-93FD-42D0-859B-BFD834899363Q38153450-A7D7C487-4FB8-45E9-B06B-34C41A001EEAQ38156029-389A8D09-1A71-4B52-9281-498E4C4899E9Q38267984-21B6F8E2-50FA-45AC-91C8-AEB9698D52C3Q38270705-9423AB79-3BF1-4074-96E6-7903D55D49D9Q38515846-3113729B-6405-483A-B048-9A72C68FC627Q38817761-6E818F84-8D2E-45D2-8B7B-6F425DF50A63
P2860
Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Attenuation of vascular permea ...... OP-R and S1P3 transactivation.
@en
Attenuation of vascular permea ...... OP-R and S1P3 transactivation.
@nl
type
label
Attenuation of vascular permea ...... OP-R and S1P3 transactivation.
@en
Attenuation of vascular permea ...... OP-R and S1P3 transactivation.
@nl
prefLabel
Attenuation of vascular permea ...... OP-R and S1P3 transactivation.
@en
Attenuation of vascular permea ...... OP-R and S1P3 transactivation.
@nl
P2093
P2860
P356
P1476
Attenuation of vascular permea ...... OP-R and S1P3 transactivation.
@en
P2093
Joe G N Garcia
Jonathan Moss
Liliana Moreno-Vinasco
Patrick A Singleton
Saad Sammani
Sherry L Wanderling
P2860
P304
P356
10.1165/RCMB.2006-0327OC
P577
2007-03-29T00:00:00Z